Business
Glaukos Announces FDA Acceptance of NDA Submission for Epioxa™
ALISO VIEJO, Calif., February 24, 2025--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the "Day 74" notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment
About this update from Glaukos Corporation
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2774,"height":518,"url":"https://media.zenfs.com/en/business-wire.com/00cf045bc2fb1d6134e6e555555fd358"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/FURAEFfQQlKGIvjjG39w4A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/00cf045bc2fb1d6134e6e555555fd358","width":960,"height":179},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/vxvytqEhVt.Nh8pmyiTOdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00NDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/00cf045bc2fb1d6134e6e555555fd358","width":1200,"height":224}},"lazy":false},{"type":"text","content":"PDUFA Date Set for October 20, 2025","length":35,"tagName":"p","attribs":{}},{"type":"text","content":"ALISO VIEJO, Calif., February 24, 2025--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced it has received the "Day 74" notification from the U.S. Food and Drug Administration (FDA) acknowledging the previously submitted New Drug Application (NDA) for Epioxa™ (Epi-on), its next-generation corneal cross-linking iLink therapy for the treatment of keratoconus, a sight-threatening corneal disease, is sufficiently complete to permit a substantive review. The Prescription Drug User Fee Act (PDUFA) goal date for the completion of the FDA’s review of the Epioxa NDA is set for October 20, 2025. This date reflects a standard 10-month review period, which is consistent with the company’s expectations.","length":883,"tagName":"p"},{"type":"text","content":""The acceptance of the Epioxa NDA represents another important step in being able to provide keratoconus patients and the ophthalmic community with the first FDA-approved, non-invasive corneal cross-linking drug therapy that does not require removal of the corneal epithelium, the outermost layer of the front of the eye," said Thomas Burns, Glaukos chairman and chief executive officer. "We look forward to working closely with the FDA throughout their review process and continue to believe Epioxa, which is designed to reduce procedure times, improve patient comfort...